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Gold nanoparticles (GNPs) are readily synthesised structures that absorb light strongly to generate thermal energy which induces
photothermal destruction of malignant tissue. This review examines the efficacy, potential challenges and toxicity from in vitro and in vivo
applications of GNPs in oesophageal, gastric and colon cancers. A systematic literature search of Medline, Embase, Web of Science and
Cochrane databases was performed using PRISMA guidelines. Two hundred and eighty-four papers were reviewed with sixteen studies
meeting the inclusion criteria. The application of GNPs in eleven in vivo rodent studies with GI adenocarcinoma demonstrated excellent
therapeutic outcomes but poor corroboration in terms of the cancer cells used, photothermal irradiation regimes, fluorophores and types of
nanoparticles. There is compelling evidence of the translational potential of GNPs to be complimentary to surgery and feasible in the
photothermal therapy of GI cancer but reproducibility and standardisation require development prior to GI cancer clinical trials.
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United Kingdom, which equates to one person every four minutes. 1
in 2 people in the UKwill develop cancer in their lifetime,1 whilst in
the United States, 1 in 3 women and 1 in 2 men will develop cancer.
In some nations, cancer will surpass heart disease as the commonest
cause of mortality.2 The incidence of gastrointestinal (GI) cancers is
increasing since the mid-1970s in the UK, and primarily includes
oesophageal, gastric and colorectal carcinomas, with a Western
preponderance towards adenocarcinomas. Colorectal and oesopha-
geal cancers are now the 4th and 8th commonest cancers worldwide
respectively.3 These cancers are often being detected rather late in
their course, as their detection relies heavily on symptomatic
reporting and on non-specific screening methods.4 The 5-yearConflicts of interest: none.
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treatment range from 5 to 20% for oesophageal cancer, 10-15% for
proximal gastric cancer and 6-75% for colorectal cancer.3,5,6
Generally the first-line treatment of solid and established
gastrointestinal tumours in the UK is neoadjuvant chemo(ra-
dio)therapy, followed by surgical excision and depending on the
grade/stage of the tumour, adjuvant chemotherapy. Single
modality treatment is largely ineffective. Chemotherapy has a
substantial failure and intolerance rate due to inadequate
localisation of drugs to cancer-specific tissues and systemic
side effects.7,8 Radiation, on the other hand is unable to eliminate
all loco-regional recurrences and cure localised cancers due to
the inherent resistance of some cancer cells towards ionising
radiation.9 Neither radiotherapy nor chemotherapy has shown
significant survival benefit,10 and the results from surgery as a
sole entity are meagre without the summative complementary
effects from chemo-radiotherapy. The need for establishing
personalised medicine as a means of providing tailor-made
targeted delivery of therapy for specific cancers to individual
patients seems increasingly essential.cess article under the CC BY-NC-ND license (http://creativecommons.org/
r gastrointestinal cancer theranostics: a systematic review. Nanomedicine:
2084 M. Singh et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 2083–2098The Nobel Prize winner Richard Feynman first proposed
nanotechnology in 1959.11 “Nano” is Greek for “dwarf” and
nanotechnology comprises particles that are of the order of 1
billionth of a metre (10−9 m). The National Nanotechnology
Initiative (NNI) defines nanotechnology at dimensions of roughly
1-100 nanometres (nm).12 By this definition, the largest
nanoparticle (NP) is approximately six to eight hundred times
smaller than the width of a strand of hair and approximately
100-10,000 times smaller than a human cell. The past 25 years has
seen an intensified interest in nanotechnology, with the develop-
ment of a multitude of different shaped NPs for material science
and nanomedicine. The commonest shapes include nanorods,13-19
nanospheres20-22 and nanoshells,23-28 but the diversity extends to
nanocubes,29-34 nanowires,35-38 nanorockets39 and nanostars40-44
to name a few. In general, NPs smaller than 100 nm have excellent
tumour targeting ability,45 being small enough to permeate out
from porous vascular endothelial fenestrations that surround a
region of tumour.
Theranostics refers to agents that are simultaneously
therapeutic and diagnostic. Theranostics using NPs implies a
robust system which can diagnose, deliver targeted therapy and
monitor response.46 When excited with laser energy with a
wavelength that is tuned to the gold nanoparticle’s (GNP)
specific surface plasmon resonance (SPR), valence electrons on
the surface of GNPs exhibit very strong oscillatory energy,
which induces high temperatures that are useful for causing
localised tissue death. When these NPs are heated within cancer
tissue, this is then termed photothermal therapy (PTT). This
photothermal reaction can be applied to kill cells within tumours,
specifically in places that are difficult to reach surgically or
require a palliative debulking procedure. The SPR of GNPs can
be tuned to absorb light in the near infrared (NIR) region to
harness the potential of applying this photothermal effect to
cancer tissue in vivo. The first use of GNPs in photothermal
ablation was described by Hirsch et al in SKBr3 human breast
epithelial carcinoma cells in 2003.15
NPs are also being used to deliver therapeutic chemicals
directly to tumour sites, by extending their ability to also act as
nano-carriers. Formulations of nanoparticles such as Doxil™,
Abraxane™, Resovist® and Feridex® are already in clinical
practice.47 Despite this progress, there remain considerable
uncertainty and variation in methods and results from the
application of GNPs in GI cancer that have been published. It is
perhaps this existing uncertainty and variation that has
forestalled the transition of GI cancer theranostics from in vitro
and murine in vivo studies to human clinical trials. By applying
GNPs that can target GI adenocarcinomas, the thermal effect that
would result from irradiation by a light source could exert an
ideal therapeutic effect on the cancer tissues. Studies have shown
that GNPs have relatively negligible cytotoxicity on healthy
cells, making them ideal for cancer-specific therapy.
Thus the aim of this systematic review is to compartmentalise
and consolidate the progress of in vitro and in vivo applications
of the most studied inorganic metallic NP- GNP - in GI cancer.
This paper aims to highlight and provide some objective
evidence into some of the current controversies surrounding
their application in the GI tract by discussing published findings
relating to their size, shape, synthesis, surface charge, active andpassive targeting efficiency, cellular uptake, biocompatibility,
drug delivery and most crucially, their toxicity. GNPs have
afforded new applications for a host of imaging platforms to
enhance optical detection of these cancers, thus these are also
reviewed. Where possible this paper attempts to elucidate if there
are any potential conclusions that can be drawn on their
optimisation, efficacy and safety, and identify any potential
issues that need addressing prior to elevating nanomedicine from
the bench to clinical practice.Background
Hyperthermia and photothermal therapy
Upon irradiation of GNPs with NIR light, surface electrons
become excited and resonate vigorously. When these electrons
return to the ground state, they emit energy in the form of heat and
the surrounding temperature is raised.48 The temperature rise is
primarily dependent upon the shape and concentration of the NPs,
incubation time of GNP with tissues, laser fluence (power per unit
area) and the laser exposure time.49,50 The characteristic
absorption spectrum of GNPs is dependent on the shape of the
particles and is usually chosen to be within the NIR spectrum
[between 650 and 900 nm for up to 10 cm depth of
penetration51-53] where there is minimal background tissue
absorption and high optical tissue penetration.46 In the case of
gold nanorods (GNRs), altering and increasing their aspect ratio
(length/width) during chemical synthesis shifts the absorptive peak
of their longitudinal SPR bandwithin the visible andNIR.54-56 The
application of gold nanospheres has rather limited spectral
tunability due to their resonance peak at approximately 520 nm
in the visible, which thus has a more limited clinical application in
GI cancer due to the absorption and scattering of this light by tissue
and endogenous chromophores.
GNP heating can also release drugs directly into the site of
particle accumulation by de-coupling heat-sensitive chemical
bonds to the nanoparticles that act as cargo carriers or vectors.
Furthermore, the photothermal effect may be channelled to
rapidly transport drugs across membranes and damage DNA and
proteins as well as generate oxygen free radicals.57,58
Within tissue, hyperthermia encourages higher concentration
of drugs to localise within a tumour by increasing regional blood
flow. Hyperthermia also works at the cellular level by increasing
cellular permeability and enables higher intracellular chemo-
therapy concentrations.57 Personalised medicine has given rise
to ‘activated therapy’, namely enzyme-cleavable prodrugs,59,60
which become active and release the parent drug after interacting
with a specific biomarker inside the cell.61 Nanotechnology has
allowed the progression of drug-delivery from bench to clinical
application. For example, an albumin-bound 130 nm particle
such as paclitaxel (Abraxane®, Abraxis BioScience Inc.) has
been approved by the US Food And Drug Administration (US
FDA) for metastatic breast cancer.62 Another FDA-approved
nanoparticle-based drug in use is doxorubicin (Doxil), which has
been validated in a phase III multiple-myeloma trial and further
indicated in metastatic ovarian cancer and AIDS-related Kaposi’s
sarcoma.63 Although there have been numerous drug delivery
systems throughout the world, very few have made it through the
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Agency (MHRA), the European Medicines Agency (EMA) or the
US FDA, indicating a formidable “bottle neck” from translating
bench to bed-side delivery.64,65
PTT using NIR light absorption to elicit thermal damage46 is
an established means of destroying cancer tissue, since tissues
heated above a certain thermal threshold undergo various
mechanisms of cellular damage66,67 such as protein structural
changes or carbonization of tissues. The term hyperthermia is
used when an organ is heated to temperatures between 41 and
45 °C. Hyperthermia can also enhance the efficacy of chemo-
therapy and radiation-induced tumour damage,68,69 and there are
also positive reports of an enhancement of the photodynamic
(PDT) response70 compared to PDT alone.71 Hyperthermia is an
attractive therapy for it retains a lower side-effect profile than
conventional cancer treatments, with the potential of repeated
application without the concern of compounding the toxicity
levels.72 One major challenge to local and regional PTT is the
development of a homogeneous temperature distribution
throughout the tissue,73 as the heating delivered from lasers
generally follows a Gaussian profile. Temperature-dependent
cell survival graphs have shown that each 1 °C temperature rise
above a 43 °C threshold leads to doubling of cell death.58
Techniques which employ temperatures above 45 °C to
produce irreversible cell damage are referred to as thermal
ablation techniques,57 such as those used in radiofrequency or
microwave ablation. This produces a specific area of cellular
death bordered by regions experiencing less intense hyperther-
mia and potentially viable. Cancer cells appear to be more
sensitive to heat-induced damage than normal cells.74
Rodent studies demonstrated that tissue depths of approxi-
mately 1 cm could be irradiated safely with NIR light using
untargeted gold nanoshells with less than 10 °C increases in
normal tissues.25 These results concur with Shah et al
demonstrating that NIR wavelengths are able to penetrate to
depths of more than 1 cm in tissues without visible damage.75
Depth of penetration and selectivity of PTT are some of the key
challenges encountered in translating this technology to patients,
where tumours may be extending 5-10 cm deep within
parenchymal structures.24
Enhanced permeability and retention effect (EPR) and tumour
targeting
First described by Maeda and Matsumura in 1986, the
enhanced permeability and retention (EPR) effect provides an
explanation for specific accumulation of GNP at the tumour
site.76,77 They explained that NPs selectively accrue within solid
tumour masses as a result of tumour physiology. Solid tumours
contain leaky blood vessels with cell junction gaps ranging from
100 nm to 780 nm,78 compared with pore diameters of up to
20 nm in normal capillaries.79-81 Studies have repeatedly
demonstrated that NPs with diameters up to 100 nm will pass
through the reticuloendothelial system (RES) and into the
circulation to extravasate and accumulate in the tumour
region.79,82-85 However, the sizes of these endothelial fenestra-
t ions are known to vary with tumour type and
microenvironment.86 Once assembled inside the tumour inter-stitium, NPs are retained due to locally ineffective lymphatic
drainage. This is a passive method of organising GNPs into
cancerous regions, so that they are optimally positioned for PTT.
For tumours less than 3 cm, local hyperthermia using targeting
derived from passive GNP accumulation may be suitable58,87 but
the biggest limitation is the considerable biological heterogeneity
of tumours and hence the lack of bio-specificity. Tumours with
poor vasculature, such as pancreatic or prostate cancer, may not
amass GNPs via the EPR effect alone.74
Active targeting has consequently been explored to enhance the
GNP concentration within the tumour matrix by attachment of a
targeting moiety that is over-expressed in cancer cells. The GNP
surface ismodifiedwith an antibody or ligand for receptor, antigen,
carbohydrate or other type of targeting.85,88 Antibodies that have
been applied in targeting gastrointestinal cancer include human
epidermal growth factor receptor 1 (EGFR), vascular endothelial
growth factor (VEGF), folic acid (FA) receptors and vascular cell
adhesion molecule-1 (VCAM-1). Two distinct targeting mecha-
nisms may be used to aid tumour specificity.
Following conjugation to a specific receptor, GNPs internal-
ise via the characteristic mechanism for that particular receptor;
for example, GNPs targeting EGFR receptors become inter-
nalised within 15 minutes of receptor-ligand engagement68 —
see section below. The biggest limitation associated with active
targeting is the fact that the GNPs are typically larger and
experience difficulty in mass transport across bio-barriers, and
also competitive uptake by non-target cell types or
extracellularly.89 This may partly explain why the current
GNPs in clinical use utilise passive targeting via the EPR effect
rather than active biomolecular recognition, as well as the more
complex clinical approval route for targeted agents.90
Synthesis and surface coating of GNPs
In 1857 Michael Faraday pioneered the synthesis of colloidal
gold; where he described a chemical synthesis of reducing gold
chloride in a carbon disulfide solvent using phosphorous as a
reducing agent.91 Today, there are three main methods to synthesise
GNPs: physical, chemical and biological. The physical methods of
synthesis comprise microwave irradiation,92 ultra-violet
irradiation,93 laser ablation,94 sonochemical methods,95 thermolytic
processes,96 photochemical and radical induced methods.97,98 The
biological method uses fungi or bacteria as nanofactories.99,100
In the synthesis of gold nanorods, which are the most widely
used GNP in the PTT of GI cancer, the most commonly used
method comprises a chemical seed-mediated approach whereby
spherical ‘seed’ NPs (~4 nm) are added to a growth solution
containing gold salt, silver nitrate, ascorbic acid and cetyltri-
methylammonium bromide (CTAB) leading to the fabrication of
GNPs with a rod-like morphology (i.e. GNRs).101,102 This was
first described in the 1920s103 and is a relatively simple and
reproducible method of obtaining a high yield of GNRs with
varying aspect ratios.104
CTAB, a cationic surfactant coating, induces a positive
charge to the surface of GNRs and in an aqueous medium, it
prevents particle aggregation due to electrostatic repulsion.16
CTAB can be cytotoxic as it can cause biomembrane and peptide
disintegration at micromolecular concentrations.105 Therefore, it
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order to effectively apply GNRs in biomedical uses. Attempting
to remove excess CTAB from newly synthesised GNRs with
successive washings, centrifugation and removing the superna-
tant CTAB, CTAB-capped GNRs at a concentration of
~200 μg ml−1 still exhibited marked cytotoxicity.106 Thus, it
is generally accepted that an outer protective coating on GNRs,
such as PEGylation, silica or poly(acrylic) acid (PAA) is
essential for most biological applications.16
In order to exploit the EPR effect, hydrophobic GNPs must
escape systemic recognition by the immune system. Cells of the
RES, particularly macrophages, are scavengers that inhibit
effective GNP treatment by phagocytosing or opsonising NPs
and thus prohibit them from gaining access to tumour cells.107
Nevertheless, the surface of NPs is easy to modify; and by
coating a hydrophilic ‘stealth’ conjugate such as polyethylene
glycol (PEG) onto their surface, the clearance by the RES organs
such as the kidney, liver, spleen, and lymph nodes is
decreased,68,85,88 whilst prolonging circulatory half-life by
10-100 fold.78,108 “PEGylation” of GNPs also provides an
external shell for ligand conjugation and prevents particle
aggregation. A disadvantage of PEGylation is that it can
potentially shield the targeting agent, which reduces the
likelihood of biorecognition.109
Cellular uptake of GNPs and dependence on GNP type and shape
NPs traversing the GI tract bypass efflux by transmembrane
ABC (ATP-binding cassette) transporters and subsequently enter
cells via endocytosis.110 The process of GNR internalisation was
studied by Chithrani et al using transferrin-functionalised GNRs.
The authors concluded that receptor-mediated endocytosis was
the main mechanism behind internalisation based on a 70%
decrease in cellular uptake at low temperatures (4 °C), which is
known to cease receptor-mediated endocytosis.111
It is important to examine the distribution of GNPs in tumours at
both tissue and cellular levels. As GNPs are electron-dense,
transmission electron microscopy (TEM) or scanning electron
microscopy (SEM) are both able to confirm internalisation of GNPs
into gastrointestinal cancer cells, observe aggregation as well as
characterise the size and shape of the GNPs. EM can also display
post-irradiation changes to intracellular architecture and organelles
after NIR light absorption by intracellular GNPs. It can also be
utilised to quantify non-selective uptake of GNPs by non-cancerous
cells and the collateral spread of PTT damage to adjacent healthy
tissues. Inductively coupled plasma-mass spectrometry can be used
to give a precise quantification of the amount of administered gold
which has been taken up by cells or tissues.105,112
There is some debate as to whether gold nanospheres, gold
nanoshells or GNRs (the three most widely applied GNPs in the
PTT of GI carcinoma) are preferable for biomedical targeting and
delivery, as they all employ the same principle of SPR to release
thermal energy to the surrounding tissues. Gold nanoshells
(approximately 10-300 nm in diameter) comprise a dielectric
core, usually silica, which is encompassed by a thin gold
shell.25,26 Huang et al found that when targeted gold
nanospheres and GNRs were compared with each other in
terms of receptor binding to malignant oral epithelial cancercells, many more GNRs appear to bind to malignant cells due to
interactions between the surface of the rods and cell surface
proteins.15 Huang also pointed out that on some occasions GNRs
also accumulated in non-malignant cells due to non-specific
interactions. von Maltzahn et al further demonstrated that
PEG-GNRs were superior to PEG-gold nanoshells in terms of
intrinsic absorption and photothermal efficacy (GNRs generated
more than 6 fold greater heat per gram of gold), as well as
significantly longer circulation times in vivo (~17 hours for
PEG-GNRs versus ~4 hours for PEG-gold nanospheres), which
may be attributable to their polymer coating.113
Chen et al evaluated GNP size-associated toxicity over time.
They found that GNPs ranging from 8 to 37 nm produced severe
sickness in mice and side effects including fatigue, anorexia, fur
colour changes and weight loss. The majority of mice injected with
these sized GNPs died before the end of the fourth week.114 It is
important tomention that the GNPs usedwere not PEGylated, rather
somewhat unconventional surface modification peptides (pFMDV
and pH5N1)were utilised. The authors also observed that very small
GNPs (5 nm) or larger (50-100 nm) were in fact non-toxic.
Desai et al explored the relationship between GNP size and GI
tract uptake and showed that GI cell endocytosis occurs more
readily when NP sizes are below 130 nm.115 It is thus presumed
that both active and passive targeting can be capitalised
simultaneously to maximise the efficacy of GNP targeting, with
the proviso that the combined particle-conjugate size remains
approximately 130 nm or smaller to avoid uptake by the RES.
NPs have a large surface area to volume ratio which allows them
to be held in suspension, incorporate targeting moieties, allow high
pro-drug encapsulation and high loading capacity for imaging
probes, but also permit extensive surface absorption.61,116-118 It is
known that most chemotherapy drugs distribute non-specifically
within the body, which accounts for much of its toxicity and side
effects. However GNPs loaded with cleavable pro-drugs are able to
specifically internalise within cancer cells. This presents an elegant
solution to the problem of non-specific biodistribution and poor
bioavailability of conventional drugs.
Positively charged nanoparticles (from zeta potential measure-
ments) were believed to be more likely to adhere to negatively
charged cell membranes119-121 by electrostatic interaction.
However, doubt remains as to what extent the charge of GNPs
influences the rate of cellular uptake.122 Arvizo et al suggested that
cell membrane potential significantly affects the uptake of GNP,
and showed that cationic GNPs were much more efficient at
depolarizing the membrane and thus being taken up by both cancer
and healthy cells, comparedwith anionic or neutral GNPs.123 Lund
et al were more sceptical of this theory and proposed that it is more
likelyNPs either enter through pre-existing cell membrane pores or
are capable of re-configuring the plasma membrane in order to
create new pores.122 They used very small NPs (5 nm) and
proposed passive internalisation by pathways which do not depend
on energy, endocytosis or lipid-raft-mediated methods. Alkilany
et al studied the cellular uptake of differently charged GNRs, and
found that particle surface charge bore no correlation to GNR
uptake.105 Zahr et al proposed that the higher the surface charge of
a GNP, regardless its polarity, the more likely it is to be
phagocytosed by macrophages and removed from the
circulation.124 In practice nanoparticle surface charge is often
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which limits electrostatic interactions with other components
within the circulation.
Imaging modalities and diagnostics
Imaging the location of GNPs enables the potential diagnosis
of cancer as NPs can be targeted to cancer using both the active
and passive approaches discussed above. It is also important to
image the location of the NPs to understand their biodistribution
and to target the laser to this precise location to gain a high level
of specificity for directed therapy.
As gold nanoparticles are an excellent optical contrast agent
(primarily through optical absorption in their SPR wavelength
bands as well as their intrinsic luminescence under two-photon
excitation) they may be imaged using imaging techniques which
utilise this property, i.e. two-photon luminescence imaging,125-127
photoacoustic imaging,126,128 narrow band imaging129 and optical
coherence tomography (OCT).13,130
NIR fluorophores such asCy5.5may be conjugated to the surface
of NPs for background-free diagnostic fluorescence imaging to
clearly localise aggregates of GNPswithin tissue. Once fluorescence
is identified within a cluster of nanoparticles, NIR laser illumination
may then be directed to that location for PTT.
Non-optical methods have also been used with GNPs such as
positron emission tomography (PET) and x-ray computed
tomography (CT). They have been used with X-rays as gold
has a higher atomic number and density compared to standard
radiosensitive iodine-based reagents.131,132 von Maltzahn et al
have shown preliminary evidence that GNRs appear to exhibit
approximately two times more X-ray contrast than that of
standard iodine per mole.113 Gold nanoshells133,134 and
nanocages135 have also been attached with the radionuclide
64Cu to enable PET imaging of the NP location.Materials and methods
This systematic review was performed in accordance with
guidelines from the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA).136
Eligibility criteria
Original peer-reviewed articles published in English on the
application of GNPs in GI tract cancer (including oesophageal,
gastric and colorectal carcinoma, but excluding oral, hepatic or
pancreatic cancers) were considered. Studies using NPs without
any gold element were excluded. Where multiple studies existed
from the same institution, the most recent study was considered.
Information sources and search
A broad literature search was conducted in May 2013 using
PubMed (1946 to date), Embase (1974 to date) and PsycINFO
(1967 to date) databases. Additional searches using the Cochrane
Library, Ovid SP and cross-referencing with Web of Science®
were used to broaden the search. The MeSH search terms used
were “gold nano*” and “*esophag*” or “gastr*” or “colo*” or
“rectal” or “*intestinal” and “cancer”.Study selection and data collection process
Two reviewers (M.S. and D.S.E.) independently reviewed all
relevant articles from the literature search. The full text of each article
was obtained and further screened for inclusion if it had relevance to
application of GNPs in GI tract cancer. Studies were excluded if they
were only conference abstracts without any extension to a full
supporting paper due to the lack of data and methods, and studies
were excluded if they only were on hepatic or pancreatic cancer. A
high level of agreement existed between both reviewers, and minor
queries were discussed between the reviewers until a 100%
concordancewas achieved on the final studies included in this review.
Data items
The following items were extracted from the studies: GNP type,
shape, average size and concentration used, type of cancer cell lines
or animal tumour model used (or both), charge of GNPs,
employment of targeting agents, methods of confirming intracellular
accumulation of GNPs, laser radiation type, fluence and regime,
confirmation of PTT effects and temperature rises, confirmation of
histological evidence of cellular destruction or cell viability studies
(for cell studies), survival studies or follow up (for animal studies),
imaging modalities used, and any evaluation of toxicity.Results
Initial searches using the MeSH terms above revealed 284
articles. There were nine conference abstracts (without accompa-
nying full papers), which were excluded. A further 48 articles were
identified through free text searches, the “related articles” feature
and cross-referencing. Once duplicates were removed, finally 16
studies remained and were found to match the inclusion criteria,
thus these are discussed in this systematic review.
GNP type and concentration
GNPs that were used in the theranostics of GI tract cancer
involved a combination of GNPs conjugated with silica,137,138
PEG,23,129,139,140 chitosan,141,142 iron core (with a gold shell 143,
pure shells,144 platinum-tethered,145 CTAB-coated GNR,146
gold-SPION hybrid NPs,147 PEG-conjugated hyaluronic acid
NPs,148 PEG-Au-TNF149 and poly(acrylic acid)-GNR.106 Al-
though there are many shapes of NPs in existence, the three
identifiable GNP shapes were rods, shells and spheres. The other
identifiable characteristics of the studies are described in Table 1.
Charge of NPs
Zhang et al measured 15 nm chitosan-coated GNPs using zeta
potentials, and found they bore a charge of +30.0 ± 1.18 mV at a
pH of 7.4.142 They proposed that the positive charge promotes
particle repulsion and prevents agglomeration, whilst enhancing
endocytosis when interacting with negatively charged cell
membranes. Huang et al also measured the zeta potential of
their synthesised GNPs, but it was unclear whether the authors
considered this to have a bearing on GNP internalisation.137
Table 1
The included studies, with the type of study, shape, size and concentration of GNPs used in the study.
Study Cells/animals Shape Ave. size (nm) GNP concentration
Huang et al137 Cells + mice Rods 46 × 18 0.625-12.5 μM
Sazgarnia et al144 Mice Spheres 6-8 38.6 μg/ml
Li et al141 Cells + rats Particles 30-90 OD 1 (cells) or 3 × 1011 NP/ml
OD 50 (animals)
Wu et al143 Cells Particles 10 10 μg/ml
Zhang et al142 Cells Particles 15 20-100 μM, OD 0.6
Puvanakrishnan et al129 Mice Shells 135 2.66 × 109 NP/ml, OD 1
Goodrich et al140 Mice Rods 45 × 14 4.5 ml/kg or OD 100 given IV to mice (2 × 1013 GNR/ml)
Brown et al145 Cells Particles 30-40 ?
Black et al146 Cells Rods 60 × 20 ?
Kirui et al147 Mice Hybrid particles 6-18 PTT — 200 μL, 1 mg/ml
MRI — 0.3 ml, 1 mg/ml
Gobin et al23 Mice Shells 119 150 μL (1.5 × 1011/ml)
Choi et al148 Mice Particles 238 ?
Paciotti et al149 Mice Particles 33 5-24 μg
Diagaradjane et al139 Mice Shells 132-135 8 × 108/g body wt.
Kirui et al106 Cells Rods 66 × 11 100 μg/ml
O'Neal et al138 Mice Shells 8-10 100 ml of 2.4 × 1011 NP/ml solution
Key: NP = nanoparticle, OD = optical density, ? = unknown/unclear.
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Twelve (75%) of the gastrointestinal cancer studies did not
involve functionalisation with a targeting agent, relying instead
solely on the EPR effect of passive accumulation of GNPs
intracellularly and into the tumour tissue.
Folic acid was used as a targeting agent for MCG803 gastric
cancer cells.137 Kirui et al adopted immuno-targeting using
humanised single-chain antibody conjugates (A33scFv) that
target the A33 antigen expressed in 95% of primary and
metastatic human colorectal cancer (CRC) cells, but is absent in
most other normal tissues and tumour types.106,147 Hyaluronic
acid receptor (CD44) that is over-expressed in various cancer
cells148 has also been employed for targeting.
Cancer models used
The cancer models used were broadly categorised to either
cellular studies (in vitro) and/or animal studies (in vivo) as shown
in Table 2.
Irradiation regimes
The irradiation regimes used with gold nanoparticles are
shown in Table 3.
Proving endocytosis of gold nanoparticles
A variety of different methods were used to identify the
uptake of GNPs into cells and tissues. Almost all studies
employed TEM imaging to visualise nanoparticles post synthe-
sis, but three studies also used it to visualise NPs within
cells137,142,145 and one study used dark field microscopy.137 It
was found that GNRs are virtually unchanged after internalisa-
tion and it is apparent that GNPs do not enter the nucleus, but
agglomerate within intracellular vesicles.137,142 The uptake and
localisation of platinum-tethered NPs were also examined usinginductively coupled plasma mass spectrometry, which confirmed
the ability of GNPs to deliver platinum inside cells.145
Fluorescent protein labelling of a colon cancer cell line was used
byBlack et al146 whilst Kirui et al usedNIR fluorescence imaging of
localised intratumoural gold-SPION hybrid NPs.147 In a prior study,
Kirui et al106 also showed that humanCRCSW1222 cells incubated
with fluorescently-labelled A33scFv-GNRs had internalised into
cells using fluorescent-based confocalmicroscopy analysis. Gobin et
al excised tumours and then cryosectioned them with silver staining
prior to microscopic analysis,23 confirming that nanoshells were
present throughout the tumours. Li et al similarly demonstratedGNP
loading in cells via histology using silver staining.141
A method used to identify iron-gold hybrid GNPs within
cancerous tissues was using Perls’ Prussian blue staining.147
Other excised tumour sections were lyophilised for gold content
evaluation using neutron activation analysis,23 which was able to
verify the presence of nanoshells within the tumour.
Photothermal effect, hyperthermia and cancer cell destruction
Photothermal effects were evaluated in all studies that involved
laser application. However, in one study suppression of cancer cell
proliferation was noted without laser illumination, which was
attributed to the GNP composition causing local cytotoxic effects.
Wu et al noted that iron clusters before oxidation in their iron
core-gold shell nanoparticles specifically inhibit the growth of human
CRC cells (CaCo-2 & HT-29), leaving healthy cells unaffected.143
Ultrasound (US) irradiation alone showed an insignificant
anti-tumour effect as shown by Sazgarnia et al. However, they
showed that acoustic cavitation in the presence of GNP with
intense pulsed light (IPL), a broadband (560-1200 nm), pulsed,
high energy light source, could be used as a new method to
improve therapeutic effects on tumours.144 The authors
discovered that tumour inhibitory effect was significant when
IPL and US and GNPs were used. They hypothesised that IPL
Table 2
Types of in vitro and in vivo GI cancer models and methods of inducing cancer in rodents.
Study Cells Animals Cell line on animals Inoculation method
Huang et al137 MCG803 human gastric cancer Nude mice MCG803 gastric cancer Flank s/c
Sazgarnia et al144 No BALB/c mice CT26 colon carcinoma tumour Flanks s/c
Li et al141 Het-1A, BAR-T and OE-19
human oesophageal lines
Sprague–Dawley rats Esophago-duodenal anastomosis
Wu et al143 Caco-2andHT-29humancoloncancercells No
Zhang et al142 Gastric cancer MGC-803 and human
gastric mucosa epithelial GES-1 cells
No
Puvanakrishnan et
al129
No Swiss nu/nu mice HCT116, ATCC#CCL-247
human colon cancer cells
Flank s/c
Goodrich et al140 No Balb/c mice CT26.wt murine colon
carcinoma (ATCC)
Flank s/c
Brown et al145 HCT116, HCT15, HT29, RKO
human colon cancer cells
No
Black et al146 HCT-116 human colon cancer cells No
Kirui et al147 No Balb/c nude mice a) SW1222 cells (antigen-expressing
human colorectal cancer cell line).
Left flank s/c
b) Human colorectal cancer
cell line (HT-29)
Right flank s/c
Gobin et al23 No BALB/c mice CT-26, ATCC murine colon
carcinoma cells
s/c
Choi et al148 No
BALB/c mice
3 models:
HT29 human colon cancer cells 1 × 107 HT 29 cells in 100 ml
saline s/c into mice dorsa.
BALB/c mice Liver-implanted with CT26
colon cancer cells
Laparotomy & direct injection
of 3 × 105 CT26 cells into the
left liver lobe.
A/J mice Azoxymethane (AOM)-induced
orthotopic colon cancer models.
Intraperitoneal injection
Paciotti et al149 No C57/BL6 mice MC-38 colon carcinoma cells s/c
Diagaradjane et al139 No Nude Swiss mice HCT 116 human colorectal cancer cells ∼2 × 106 cells s/c into
right thigh.
Kirui et al106 SW 1222 (106 cells/ml)
human colorectal cancer cells
No
O'Neal et al138 No BALB/c AnNHsd
Sprague–Dawley mice
CT26.WT murine colon
carcinoma tumour cells (ATCC)
s/c into flank
Key: s/c = subcutaneous injection.
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nucleation sites for acoustic cavitation.
Huang et al noted that gastric cancer cells incubated with
GNR-SiO2-FA, destroyed cell spindle morphology, ruptured cell
membranes and produced significant scarring after 3 minutes of
NIR laser (4 W/cm2) application.137 X-ray irradiation was also
utilised on chitosan-modified GNPs (CS-GNPs), and the survival
fractions of gastric cancer cells treated with CS-GNPs decreased
when increasing the concentration of CS-GNPs and when
compared to cells without CS-GNPs under the same X-ray
radiation dose.142 Kirui et al proved effective PTT of CRC cells
that had been incubated with plasmon-resonant A33scFv-GNRs
and treated with NIR laser (5.1 W/cm2) for 5 minutes.106
In measuring local tissue temperatures achieved from PTT,
Goodrich et al noted that in a mouse study, the average
maximum temperature difference for GNR-infused and laser-
treated animals was approximately 32.1 ± 9.0 °C. In tissues
undergoing GNR-assisted laser PTT, they observed maximum
temperatures of approximately 62.0 ± 9.0 °C in tissues, whilst
with the laser-only control animals the maximum tissue
temperatures were approximately 45.3 ± 2.8 °C. These temper-ature rises were noted over a 3-minute NIR laser (3 W)
irradiation period.140 Kirui et al noted a 30 °C temperature rise
for a concentration of 0.5 mg/ml hybrid NP using a regime of 7
rounds of NIR CW irradiation (5 W/cm2) over a fortnight.147
O'Neal et al demonstrated after 30 seconds of NIR irradiation
(4 W), the average temperature of laser-nanoshell treated colon
cancer in mice was approximately 50 °C and this was
statistically significantly higher than the nanoshell-free (but
NIR irradiated) controls. A complete tumour resorption was seen
after 10 days of laser-nanoshell treatment.138
Diagaradjane et al used H & E (haematoxylin & eosin) to
demonstrate there were necrotic regions at a distance
of ∼1.4 mm from the tumour periphery in their thermora-
diotherapy group, which showed a distortion of regional
architecture characterised by patchy hypoxic regions in the
tumour core with no identifiable regions of blood flow.139
Histological evidence of destruction and cell viability studies
The effects of PTT on cells using GNPs should be evaluated
to ensure selective cellular destruction of cancer cells and the
Table 3
Irradiation regimes used in each study model.
Study Cells/animals Irradiation used Laser power & fluence Duration of radiation
Huang et al137 Cells & mice CW laser 808 nm 30 mW laser power
4 W/cm2 laser fluence
3 mins
Sazgarnia et al144 Mice Intense pulsed light (IPL)
(LumenisOne), a broadband
(560-1200 nm), pulsed, high
energy light source + US
US: 2 W/cm2, with frequency 1.1 MHz
Light: 35 J/cm2
US — 3 mins
IPL — 9 pulses of 5 ms
pulse duration
Li et al141 Cells & mice CW laser 818 nm — used both
externally & via microendoscopy
3 W/cm2 Cells & rats, 1 min at
3 W/cm2, or, 30 sec, 1 W/cm2
Zhang et al142 Cells X-rays 1 Gy/min Cells exposed to 2, 6 & 10 Gy
with corresponding irradiation
times of 2, 6 & 10 min
Goodrich et al140 Mice CW laser 808 nm 3.5 W at 4.46 W/cm2 180 seconds
Black et al146 Cells Ti:Sapphire at 800 nm 1 mW (imaging), N10 mW for PTT
with beam diam. approx. 20 μm
No time duration specified just
states “4 passes"
Kirui et al147 Mice CW laser 808 nm 5 W/cm2, 6 mm diam 30 mins & 7 rounds therapy
over 14 days
Gobin et al23 Mice CW laser at 808 nm 4 W/cm2, spot size 5 mm 3 mins
Diagaradjane et al139 Mice 808 nm CW laser + a single
10 Gy dose of radiation therapy
using 125 kV X-ray operated at 20 mA
0.6 W used, 75% duty cycle, average
optical irradiance (350 mW/cm2)
10 mm diam
20 minutes
Kirui et al106 Cells CW laser 808 nm 5.1 W/cm2 with beam size 4 mm diam 10 mins
O'Neal et al138 Mice CW laser 808 nm 4 W/cm2, 5 mm diam 3 mins
Key: CW = continuous wave, US = ultrasound, Gy = Gray (joule/kg).
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used a variety of methods in this endeavour to demonstrate
cytotoxicity or apoptosis, chiefly using trypan blue
staining,137,146 H & E staining and microscopy,139-141,144
Annexin V-fluoroisothiocyanate (FITC) apoptosis detection
kit I,143 ApopTag® apoptosis detection kit141 and assays such
as WST-1,143 CCK-8,137 MTT,141,142,145 TUNEL141 and
clonogenic cell survival assays.142 The clonogenic cell survival
assay is an in vitro assay based on the ability of a single cell to
reproduce to form a colony after ionising radiation, i.e. its
survivability.142 The MTT assay is a quantitative colorimetric
method to evaluate cytotoxicity whilst trypan blue is an in vitro
cytotoxicity assay that measures cell membrane integrity.
Brown et al evaluated the cytotoxicity of platinum-tethered
GNPs (as a chemotherapy nanovector) against traditional
PEGylated GNPs on human colon cancer cell lines using a
tetrazolium dye-based microtitration assay, an MTT assay and
inductively coupled plasma-mass spectrometry. Tetrazolium salt
assays measure mitochondrial activity. Whilst the PEGylated
NPs showed no cytotoxicity, the platinum-tethered gold
nanoparticles in contrast were found to be 5.6-fold more
cytotoxic than oxaliplatin.145 Another study also endeavoured
to determine cellular viability using 0.5% trypan blue, a dye that
does not penetrate the cytoplasm of viable cells, which were
added prior to laser treatment of CTAB-coated GNR on a human
colon cancer cell line, HCT-116.146 After 10 minutes of
illumination, it was noted that trypan blue had entered several
cells within the laser region, and after 25 minutes, the entire
irradiated region which had initially absorbed GNRs was stained
with trypan blue, whilst other control regions remained
unchanged. A subsequent wash of the stained cells on a slide
led to the complete removal of thermally affected cells,
suggesting major cellular damage.PEG-conjugated hyaluronic acid nanoparticles (P-HA-NPs)
that contained the anticancer drug irinotecan (IRT) were studied
on 3 BALB/c mice colon cancer xenografts. It was noted that
IRT released gradually from NPs within 12 hours and then
exerted a dose-dependent cytotoxicity on colon cancer cells.148
Kirui et al conducted cell viability studies using an MTT assay of
SW 1222 cells (an antigen-expressing human CRC cell line)
after incubation with increasing concentrations of polyacrylic
acid-GNRs against CTAB-GNRs. A dose-dependent toxicity
was noted with a significantly higher cytotoxicity for cells which
were incubated with CTAB-GNRs.106
Survival studies and tumour regression— in vivo animal studies
This review considered all longitudinal survival studies and
tumour volume regression. Sazgarnia et al144 continued
follow-up for 70 days after IPL + US + GNP treatment and
noted the survival fraction of these mice was the most significant
compared with other control groups. In a different study
involving mice inoculated with CT26.wt murine colon carcino-
ma, the mean survival time with various treatment modalities
was established. For the "no treatment" group, mice lived for an
average of 8 days, whilst mice in the “laser illumination only”
group lingered for an average of 9.5 days, whilst the “NRs-only”
group survived for 9.7 days. Most significantly, it was the
photothermal ablation group of mice that lasted longest at
42.1 days.140 44% of the GNR and laser-treated mice survived at
day 60, together with evidence of complete tumour ablation. It
was observed that the mean survival time of the photothermally-
treated group was statistically higher than the control groups.
O'Neal et al observed colon tumour size and survival for 90 days
following a single NIR irradiation treatment in mice receiving IV
gold nanoshells. At 90 days post-treatment, 100% of the gold
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However, tumours in both sham and control groups continued to
develop rapidly.138
In a study by Gobin et al, tumour size and animal survival were
monitored 7 weeks after NIR treatment in CRC induced in mice
that were subjected to PEGylated gold nanoshells. All but two
nanoshell-treated mice had complete tumour regression.23 A
14 day median survival was observed in the “saline + laser
group”, and 10 days for the “no treatment” control group. After
21 days, the group with the most statistically significant survival
was the “nanoshell + laser” group, which continued until the end
points of the study. It was noted that themedian survival time could
not be calculated for this group, as the long-term survival was 83%.
In a drug-delivery study, Choi et al148 used the anticancer drug
irinotecan (IRT) attached to PEG-hyaluronic acid nanoparticles
(P-HA-NPs) on 3 mice bearing CRC xenografts. Tumour volume
and survival rates were determined after IRT-P-HA-NPs were
given intravenously every 3 days. The authors found that the
“saline only” and “free IRT” groups experienced a rapid and
significant increase in tumour size and growth. In contrast,
significant tumour growth suppression was observed in the group
treated with IRT-P-HA-NPs. 50% of mice treated with “free IRT”
died after 15 days, and approximately 90% of mice in this group
perished within 28 days, indicating IRT by itself results in severe
systemic toxicity. Nonetheless the group treated with IRT-
P-HA-NPs (using GNPs as a nanovector to deliver the drug into
cells) exhibited a much higher survival rate than all control groups.
Imaging modalities
Huang et al evaluated theHounsfield units (HU) ofGNR-SiO2 by
CT. Nude mice implanted with gastric cancer MGC803 cells were
selected as the animalmodel andX-ray imagingwas used tomonitor
the targeting ability of GNR-SiO2-FA into tissues.
137 Puvanakrish-
nan et al used NIR narrow band imaging in Swiss nu/nu mice
inoculated subcutaneously with human CRC cells to image the
accumulation of PEGylated gold nanoshells at the tumour site.129
NIR narrow band imagingwas performed ex vivo on excised tumour
tissue, and in 4 of 5 gold nanoshell-injected mice, the gold nanoshell
regions were visible as dark areas.129 Kirui et al implanted two colon
cancer cell lines subcutaneously in murine models and injected
intravenous targeted gold-SPION hybrid nanoparticles
(HNPs)-A33scFv and scanned the mice in a 7-T scanner. As a
MRI agent, HNPs which had accumulated in subcutaneous CRC
reduced the post-contrast T2 phase value by half.147 Gobin et al used
OCT imaging to evaluate PEGylated gold nanoshells in murine
CRC. The results showed no enhancement in layers of normal tissue
in mice treated with nanoshells, but there appeared to be a
significantly enhanced brightness in the region where nanoshells
accumulated within a tumour, suggesting that gold nanoshells are
able to provide substantial contrast in OCT imaging.23
Toxicity of gold nanoparticles
Huang et al showed using aCCK-8 assay that therewas negligible
cell death and physiological changes inMGC803 gastric cancer cells
after exposure toGNR-SiO2-FA. Evenwith the highest concentration
of GNR-SiO2-FA, cell viability was greater than 90%, indicating that
their GNPs were by themselves non-cytotoxic to MGC803 cancercells within the concentration range studied.137 Similarly Zhang et al
evaluated the cytotoxicity of chitosan-modified GNPs (CS-GNPs) to
MGC803 (gastric cancer) and GES-1 (human gastric epithelium)
cells using the MTT assay. The cell viability of MGC-803 cells and
GES-1 cells was more than 90% even when the concentration of
CS-GNPs was increased to 100 μM, and no decline from this high
survival rate was seen even after increasing the incubation time to
72 hours, implying very low levels of cytotoxicity.142
Li et al showed that their chitosan GNP (CS-GGS) only heated
and caused PTT in the presence ofNIR irradiationwhen absorbed by
cancerous oesophageal cell lines (OE-19). They induced orthotopic
oesophageal cancer in rats four months after forming an
oesophagoduodenal anastomosis.141 The same GNP-laser combi-
nation did not have any effect on benign human squamous
oesophageal epithelium cells (Het-1A) or Barrett’s epithelium
(BAR-T). However, the authors cautioned about selectivity of
therapy, as they found some regions in the oesophageal mucosa that
included both cancerous and adjacent healthy tissues which were
“burned” on exposure to NIR. They postulated that this could be due
to infiltration of adjacent tissues by inflammatory cells such as
phagocytes, and advised that further evaluation of the specificity of
GNP uptake in cancerous and benign tissues is required.
Goodrich et al conducted biodistribution studies in twelve
mice receiving infusions of high concentrations PEG-GNRs
(optical density of 50 or 6.5 × 1012 GNR/ml, giving 6 ml/kg
body weight). At one, seven and 28 days post-infusion, some
mice were sacrificed and blood and major organs (namely brain,
heart, lungs, kidneys, liver, spleen and lymph nodes) and
representative tissue samples were harvested for neutron
activation analysis to determine gold content. They found
concordance with other published results about the clearance
and accumulation of GNPs by the organs of the reticuloendo-
thelial system. The largest accumulation was found in the liver
and spleen, where 75% of the total injected nanoparticles were
noted 24 hours post injection, with negligible accumulation of
gold in other organs. There was a gradual clearance of the GNRs
from the liver over the 28-day study. Reassuringly there were no
signs of acute toxicity from GNRs even at 60 days.140
Choi et al used PEG-conjugated hyaluronic acid nanoparti-
cles (P-HA-NPs) loaded with the anticancer drug irinotecan
(IRT) on three mice with colon cancer. Microscopic examination
of major organs and tumours using H & E staining suggested that
IRT-P-HA-NPs was effective at destroying tumour tissues, but
only piecemeal necrosis was observed in the liver tissues.148
Paciotti et al149 evaluated tumour volume regression resulting
from various TNF treatments and treatment efficacy by varying the
doses of TNF given either in its native form or colloidal-gold bound
TNF (cAu-TNF) preparations. They noticed that at a dose of 24 μg
of pure TNF per mouse, all the mice died, yet at the same dose of
colloidal-gold-TNF preparation, not only was there a significant
tumour volume reduction, none of themice became sick or perished.Summary of evidence
Gold nanoparticle type and concentration
With the exception of one study that used GNPs of 238 nm,148
all other studies have used GNPs (of different shapes) below
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published studies looking at optimising the EPR effect, including
Desai et al who looked specifically at GI tract uptake.115 There
have been a variety of differently shaped particles being utilised in
gastrointestinal cancer targeting, including spheres, rods, shells
and seven studies which only mention “nanoparticles”, which are
uncategorised as the final shape is not described.
It is difficult to categorise the concentrations of GNP
solutions used, as most studies have not used a standardised
system to report the concentrations used. There is a wide
disparity in the optical densities (OD) of GNPs used in mice
studies, some using concentrated solutions with an OD of 100
whilst another used an OD of 50141 or an OD of 1.129 Two
studies23,138 used virtually the same concentration of nanoshells
in their mice studies, however they used vastly different
volumes. They also had different sized nanoshells, which present
too many confounding factors to make the concentrations of
various GNPs a comparable entity between studies. It therefore
becomes impossible to elucidate an effective or optimal dose for
cancer therapy, or to even establish a safe recommended dose.
None of the studies ventured to quantify what dose may
potentially be lethal or harmful in vivo.
Charge of nanoparticles
There has really been only one proponent of maintaining a
positive GNP charge,142 which, in itself suggests that charge is
unlikely to be of any consequence. It appears that most GI cancer
uptake studies rely primarily on the passive efflux from
endothelial fenestrations via the EPR effect, and secondarily
using biochemical targeting agents.
EPR effect — passive targeting
Most studies 12/16 (75%) did not involve GNP functional-
isation with a targeting agent, solely utilising the EPR effect for
tumour localisation. Goodrich et al state that their previous
experience using the concept of EPR for assessing the
biodistribution of infused GNP to tumour found that less than
10% of the total injected dose actually reaches the tumour.140
Biological agents — active targeting
Folic acid was used for targeting gastric cancer cells137 whilst
the A33 antigen106,147 and hyaluronic acid receptor148 were used
in targeting CRC. It remains to be proven if there is a definite
combination of active and passive targeting that would provide
ideal cancer targeting, but this would need to be balanced against
the risks of provoking heat-induced bleeding or perforation if
applied on more advanced (T3 or T4) cancers.
Cancer models used
There have been eleven in vivo rodent experiments, mostly
with superficial tumours inoculated through subcutaneous
injection of cancer cell lines in rodents.23,129,137-141,144,147-149
Other ways of inducing cancer include intraperitoneal injection
of azoxymethane (AOM) in A/J mice. AOM treatment is used to
induce colonic tumours as it mimics the adenoma-to-carcinoma
sequence of CRCs in humans.148 Oesophageal cancer was
induced orthotopically by mucosa-to-mucosa anastomosisbetween the lower oesophagus with the duodenum.141 In this
study, GNPs were sprayed onto the surface of suspicious
oesophageal mucosa via microendoscopy. The authors chose to
do this as they cautioned that there is a real risk of GNPs
becoming trapped in the interstitium of benign tissues with direct
injection of GNPs.
The most common gastric cancer cell line used to induce cancer
in murine models was MCG 803, whilst a variety of different cell
lines were used to induce CRC, including (in order of popularity)
CT26.wt (ATCC), HCT 116, HT-29, MC-38, SW1222 CRC cell
lines. With regards to cancer cell studies, there is only one
oesophageal study,141 one gastric cancer142 and four colon cancer
ones.106,143,145,146 Overall, there has been a lack of published studies
using the same cancer model, laser regimes, fluorophores and GNPs
(including similar concentrations) to make a valid and objective
appraisal about the ideal protocol for a particular tumour type or the
extent of its reproducibility. This is perhaps one key element that has
hindered the progression of GNPs in clinical trials for GI cancer,
whereas trials in other cancers have gone the distance. It highlights a
need for more vigorous reporting on these key elements.
Irradiation regimes
Vital pre-requisites for successful PTT include particle
accumulation and appropriate laser dosimetry at an appropriate
balance, for too high a laser exposure will entail excessive
heating and collateral tissue damage, whilst too low a laser dose
may mean incomplete ablation.140
For cell studies, a mean laser fluence of 4.0 ± 1.1 W/cm2 was
used, whilst in rodents, a mean of 3.5 ± 1.7 W/cm2 was applied
for PTT. Most studies involving PTT used CWNIR laser, except
one relying on acoustic cavitation induced by US (which also
used intense pulsed light), two studies used X-rays and one a
Ti:Sapphire laser. It is vital to accurately measure the thermal
energy being delivered and the heating occurring, either with a
thermal imaging camera or a thermocouple. Equally crucial is the
laser beam diameter and distance from the tip of the laser fibre to
the tumour’s surface for a real appreciation of the fluences
required for the thermo-ablative responses seen.
Photothermal effect, hyperthermia and cellular destruction
Whilst CW NIR lasers have been applied in eight studies for
PTT and hyperthermia in GI cancer cells and tissues, only three
have mentioned the temperature peaks achieved. One study used
intense pulsed light in combination with US irradiation and GNP
as a novel way to gain the therapeutic effect. X-ray irradiation
was also used effectively in conjunction with CS-GNPs for
thermal destruction of gastric cancer cells. The maximal
temperatures obtained by irradiating in vivo GI cancer tissues
in the presence of GNPs ranged from 50 to 62 °C, but the three
studies comprise different GNPs, concentrations and laser
power. From these GNP studies, the mean laser fluence required
to heat tissues to this temperature range was 4.5 W/cm2.
It remains debatable whether there is a time-dependent peak
of intracellular GNP concentration giving rise to an optimal
therapeutic window for laser application. This issue should be
addressed in future studies, and would involve imaging GNPs at
various time points.
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There is consensus that once internalised, GNPs do not enter
the nucleus, but aggregate in vesicles within the cell. TEM is the
most commonly used imaging modality employed to determine
the size, shape and intracellular location of GNPs. Other
techniques shown to be applicable for imaging GNPs within
GI cells and tissues include dark field microscopy, inductively
coupled plasma mass spectrometry, fluorescence protein label-
ling and imaging, fluorescent-based confocal microscopy, silver
staining, Perls’ Prussian blue staining (for iron-gold hybrid NPs)
and neutron activation analysis.
Histological evidence of destruction and cell viability studies
All studies used a variety of methods to assess cell viability
after cell or tissue treatment with thermoradiation. The three
most commonly used methods to demonstrate cytotoxicity or
apoptosis were H & E staining and microscopy, followed by
MTT assays and trypan blue staining.
Survival studies/follow-up — in vivo animal studies
Five studies presented longitudinal data from the application
of GNPs and PTT. Two of these suggested that all murine
models of CRC survived and nearly all had complete tumour
regression after GNP and irradiation treatment.23,138,148 Where
survival was studied, it is without doubt that the group of animals
which received the combination of GNPs and laser lived the
longest, and their survival was always statistically significant
compared to other interventional arms.140,144,148 It is thus
encouraging that when applied in vivo as a therapeutic modality
for GI cancer, the GNP and NIR combination appears effective at
regressing tumour and prolonging survival. This is the single
most important therapeutic information that is consistently
demonstrated in this review, and could potentially establish a
firm foundation for clinical translation.
Imaging modalities
GNPs have potential as X-ray and CT contrast agents due to
their ability to induce strong X-ray attenuation150 and are actively
being investigated as a radiosensitiser. Within GI cancer, GNPs
have been used as contrast agents in imaging modalities as diverse
as MR, OCT, NIR narrow band imaging and CT. The images
obtained can also be used to monitor targeting and response to
treatment. Kirui et al synthesised iron-gold hybrid nanoparticles
(HNP) and suggested that the iron oxide portion of the HNP served
as the MR imaging agent, whilst the gold NP portion formed the
hyperthermia agent.147
Toxicity of gold nanoparticles
Data obtained from a host of methods including CCK-8, MTT
assay, inductively coupled plasma mass spectrometry, neutron
activation analysis and microscopy show no apparent cytotox-
icity of GNP on cancer or healthy cells without the use of laser
irradiation. This is important to know as there may be
non-specific binding of GNP to non-cancerous cells/tissues,
and the route of administering GNPs into the systemic circulation
avails itself to this probability. In an in vivo study comparing thedifferent routes of administering GNPs and their corresponding
toxicities, the authors noted that the oral and intraperitoneal routes
demonstrated the highest toxicity levels, whilst the systemic route
via the tail vein seemed to show the least toxicity.151
The GNPs used in the studies have shown PEGylation is a
reliable method of protecting cells from any potential cytotox-
icity from CTAB. Goodrich et al suggest that the largest
accumulation of GNP in vivo was in the tumour followed by the
liver and spleen, and the liver and spleen together accounted for
approximately 75% of the injected GNPs on the first day,140 but
this gradually clears without any signs of acute toxicity
throughout a 60 day period.Discussion
The information presented here is encouraging in demonstrating
that GNPs do have the potential to be excellent tumour targeting
agents due to their ability to extravasate from leaky endothelial walls
surrounding a GI cancer, and remain in-situ sufficiently long to
absorb NIR light and generate heat that is capable of destroying
cancer cells. Active targeting to tumours can also be accomplished
by conjugationwithmoieties that are over-expressed on cancer cells,
namely antibodies, folic acid and peptides.
Further chemical refinement of NPs is being developed, such
that the cytotoxicity of these particles is becoming much less
pronounced. Despite the GI studies that have been conducted, we
appear to be far away from conducting a clinical trial, unless
there is a concerted effort to minimise variations in synthesised
GNPs and the concentrations used in in vivo experiments. Thus
further GI theranostics research needs to focus on the challenges
remaining in representing nanotechnology as a viable and safe
adjunct to surgery. This focus should not solely be on proving
tumour regression, but also on examining acute and long term in
vivo toxicity, with sufficiently powered studies which assess safe
and optimal GNP doses and laser fluence.
This systematic review has identified a cohort of in vivo
studies using GI cancer cells that have been implanted and grown
subcutaneously in rodents, however there have only been 2
studies141,148 where the tumour has actually been established in
an orthotopic (in-situ) model. Thermally ablating a superficial
surface tumour with an external laser beam would present a
lower risk profile than attempting the same endeavour
intracorporeally with endoscopically-delivered NIR irradiation,
where there would be additional factors and challenges to
consider, but is vital to adequately assess and quantify that risk.
In order to accomplish this, more orthotopic models of cancer
should be studied with different modes of administering GNPs
(intravenous, intratumoural or spraying) and laser treatment, to
address the factors involved in bringing this technology to the
forefront of clinical application. The depth of NIR penetration
that can be efficaciously applied to a GI tumour region also needs
to be quantified, so as to be certain about its applicability when
given through the surface of the skin or organ. It is interesting in
itself that none of the studies in this review provided any
information about the absorption or attenuation co-efficients of
tissues with or without GNPs, but this is a factor that limits the
depth of effective NIR delivery and thus heating.
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optimal photo absorbance for clinical application, as it can be
delivered deep into tissues by avoiding absorption or scattering
by tissues and endogenous chromophores such as haemoglobin
or bile. To take advantage of this clinically, it is imperative to be
able to fibre-optically couple the delivery of NIR laser to
pre-existing endoscopic and laparoscopic instruments, such that
tumours that contain functionalised GNPs can be simultaneously
identified and treated by NIR irradiation. Establishing this form
of optical coupling and image-guided tumour therapy should be
tested as a repeatable minimally-invasive procedure. Moving
nanotechnology from the bench to the clinical arena will not only
diminish the overall side-effects from non-specific systemic
treatment (such as chemoradiation), it may also reduce collateral
damage to healthy tissues.
Some of the impetus for improving the quality of in vivo GNP
studies should be because it is anticipated that some cancers
would be detected early through fluorescence imaging acquired
during endoscopic procedures. Simultaneous PTT could then be
performed at the same sitting whilst under sedation, arguably
avoiding the need for general anaesthesia, whilst reducing
personnel requirement, hastening post-procedural recovery and
facilitating earlier discharge. It would also dramatically reduce
surgical time, for example in early upper or lower GI cancers,
performing endoscopic mucosal resection (EMR) or endoscopic
submucosal dissection (ESD) would take the endoscopist a couple
of hours, but the application of targeted laser via endoscopy would
take a few seconds. This augurs well with today’s enhanced
recovery programmes, where there is a drive for more directed
therapy, improved outcomes, reduction in soft tissue trauma,
reduced complications/risks, reduced length of stay and cost-
effectiveness. Nanotechnology also has the potential of being
complementary to surgery, by being applicable post-operatively to
tumour cavities and lymphatic tissues in order to reduce the risk
of recurrence.
Equally important an issue for consideration in active targeting
is tumour heterogeneity. Cancers are unique and vary from organ
to organ, involving a mixture of malignant, non-malignant, stem
and progenitor cells.152 It remains to be answered if it is possible to
overcome this phenomenon by utilising the optical property of
GNPs. It is envisaged that this could be performed by direct
intratumoural injection of GNPs into the GI cancer, and then
irradiating the sitewithNIR.Thiswould have a particular palliative
interest, primarily being useful in patients who are unfit for surgery
or those who require tumour debulking for symptomatic relief, for
instance from dysphagia due to tumour ingrowth from a stented
oesophageal carcinoma, vomiting and aspiration pneumonia from
gastric outlet obstruction or subacute bowel obstruction from a
difficult-to-stent and stenosing colorectal adenocarcinoma. Should
there be sufficient grounds for a human clinical trial, it would be
possible to extend this application to low volumemetastatic lesions
in the liver or peritoneum, whereby GNPs could be visually or
ultrasonically injected intratumourally and NIR laser would then
be delivered through fibres during concurrent laparoscopy. The
procedure is likely to need repeating, depending on the size and
location of the lesion, but it should be relatively quick to do and
uncomplicated, and could potentially significantly diminish the
systemic inflammatory response syndrome and the surgical risksinherent from a hemi-hepatectomy. In addition to the benefits of
utilising nanotechnology in late cancers, there remain unexplored
yet intriguing avenues in the theranostics of early mucosal and
submucosal tumours using a combination of optimal imaging
techniques and targeted PTT, which are viable research platforms
for the screening and timely management of such lesions.Conclusions
This is the first systematic review that has scrutinised the studies
and collated results from the application of GNPs in the
theranostics of upper and lower gastrointestinal cancer. The
incorporation of a surface coating has certainly increased the
biocompatibility and decreased the cytotoxicity of GNPs.
Longitudinal survival studies of mice infused with varying
volumes and OD of GNPs demonstrated much-needed objective
confirmation that all the animals remained healthy during the study
period, with evidence of prolonged survival in PTT studies.
Although there appears to be an initial transient accumulation of
gold chiefly in the liver and spleen after intravenous administra-
tion, this gradually dissipates sufficiently with no long-term
sequelae or signs of toxicity in all in vivo studies.
The role of GNPs in providing diagnostic information is derived
from the fact that GNPs are inherently dynamic optical contrast
agents coupled with the ability to be further functionalised with NIR
fluorophores which lend itself to being used in a variety of imaging
techniques such as two-photon luminescence imaging, photoacous-
tic imaging, narrow band imaging and optical coherence tomogra-
phy. This feature of optical absorption contrast and fluorescence to
detect the location ofGNPswithin cancerous tissuewould also guide
the targeting of the NIR laser beam for therapy.
In terms of quantifying the efficacy of treatment on GI
adenocarcinoma, all studies conducting photothermal therapy
with gold nanoparticles showed cancer cell destruction and
in vivo effects ranging from tumour volume regression to
complete remission. The hyperthermia induced by laser
irradiation appeared to concentrate specifically on the tumour
area, with sparing of surrounding healthy tissues, enabling this
technology to ultimately be a useful adjunct to surgery and be
delivered in a minimally invasive way. Before such an
undertaking can be realised, concordance should be reached
with regards to the type, size and concentration of GNPs, with
the identification of a more robust, consistent and reproducible
irradiation regime. Given the evidence of their safety and
efficacy, achieving this congruity would provide the final
necessary credentials to establish a much-needed clinical trial
of gold nanoparticles in human GI cancer theranostics.
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